Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06735248 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 17 sitesv8
  2. Study sites: 16 to 17v7
  3. Study sites: 15 to 16v6
  4. Study sites: 1 to 15v5
  5. Eligibility criteria expanded, about 16 wordsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 28, 2025 to Apr 16, 2025
    • Eligibility criteria expanded, about 69 words
    • Secondary endpoints: 11 to 8
  2. Start date: Dec 31, 2024 to Apr 28, 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
Multiple Sclerosis
1,011 trials monitored
See 34 trials at risk
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Trial Details
NCT Number NCT06735248
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Multiple Sclerosis
Related terms Multiple Sclerosis
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov